Zaremba Rabourn Amy 4

What Happened

• Amy Zaremba Rabourn, Head of Financial Quality Assurance at Opus Genetics (ticker: IRD), received a grant of 86,500 restricted stock units (RSUs) on January 22, 2026. The Form 4 reports an acquisition price of $0.00 (code A — award/grant), meaning no cash was paid for the award at grant.
• The RSUs do not represent immediately tradable shares; they vest over time per the plan (see Key Details). This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (timely filing).
• Instrument/amount: 86,500 restricted stock units (reported acquisition at $0.00; no immediate cash value shown on the Form 4).
• Shares owned after transaction: not specified in the provided filing.
• Footnote (vesting): The RSUs "vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters," subject to the reporting person’s continued service.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax withholding, or late filing noted in this filing.

Context

• RSUs convert into common shares only as they vest; the economic value realized will depend on Opus Genetics' share price at each vesting date.
• Awards like this are a form of compensation/retention for employees and are routine internal transactions; they are not an open-market buy or sale and therefore shouldn’t be read as a direct bullish or bearish trade.